-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

616.P1.76 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I

Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 5, 2015: 5:30 PM-7:30 PM
Hall A, Level 2 (Orange County Convention Center)

Jeffrey E Rubnitz, MD, PhD1, Ronda Kaufman, PhD2*, Raul C. Ribeiro, MD3, Boris Klebanov, MA, MS4*, Joel Ellis, PhD4*, Yosef Landesman, PhD4*, Hagop Youssoufian, MD2*, Tami Rashal, MD2* and Sharon Shacham2*

1Oncology, St. Jude Children's Research Hospital, Memphis, TN
2Karyopharm Therapeutics, Inc, Newton, MA
3St. Jude Children's Research Hospital, Memphis, TN
4Karyopharm Therapeutics Inc., Newton, MA

Haifa Kathrin Al-Ali, MD1*, Nadja Jaekel, MD2*, Karolin Hubert1*, Rainer Krahl, Ph.D3*, Mathias Haenel, MD4*, Georg Maschmeyer, MD5, Regina Herbst, MD4*, Christian Jakob, MD6*, Susann Schultze, MD7*, Song-Yau Wang, MD7*, Oana Brosteanu, PhD8* and Dietger Niederwieser, MD7

1University of Leipzig, Leipzig, Germany
2Hematology and Oncology, University of Leipzig, Leipzig, Germany
3Department of Hematology and Oncology, University Hospital of Leipzig, Leipzig, Germany
4Klinikum Chemnitz, Chemnitz, Germany
5Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany
6Klinikum Ernst von Bergmann, Potsdam, Germany
7University Hospital of Leipzig, Leipzig, Germany
8Zentrum fuer Klinische Studien, University of Leipzig, Leipzig, Germany

Raoul Tibes, MD, PhD1, Heidi E. Kosiorek, MS2*, Amylou C. Dueck, PhD2, Lisa Sproat, MD, MSW3, Jeanne Palmer, MD4*, James L. Slack, MD5, Devinder Singh, MD6*, Eileen Gebhart, MSN, RN, ANP-BC7*, Emily Knight, RN8*, Shahrukh K. Hashmi, MD9, Ryan A Wilcox, MD, PhD10, James M Bogenberger, PhD11, Ruben A. Mesa2 and Aref Al-Kali, MD12

1Division of Hematology and Medical Oncology, Mayo Clinic Arizona, Phoenix, AZ
2Mayo Clinic, Scottsdale, AZ
3Division of Hematology and Medical Oncology, Mayo Clinic Arizona, Scottsdale, AZ
4Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, AZ
5Department of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ
6Hematology/Medical Oncology, Arizona Center for Cancer Care, Glendale, AZ
7Arizona Center for Cancer care, Glendale, AZ
8Mayo Clinic Arizona, Scottsdale, AZ
9Division of Hematology, Mayo Clinic, Rochester, MN
10Hematology, Mayo Clinic, Rochester, MN
11Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ
12Mayo Clinic, Rochester, MN

Rodrigo Omar Jacamo, PhD1*, Hong Mu, MD, PhD2*, Qi Zhang1*, Dhruv Chachad, MS1*, Wang Zhiqiang3*, Wencai Ma, PhD4*, Min Zhang, MD, PhD3*, Po Yee Mak, MPhil1*, Duncan Mak, BSc, MPhil1*, Peter Ruvolo, PhD1, Teresa McQueen1*, Scott Lowe5*, Johannes Zuber, MD, PhD6*, Dirk Eulberg, MBA7*, Anna Kruschinski7*, Marina Konopleva, MD, PhD1, R Eric Davis, MD4* and Michael Andreeff, MD, PhD8

1Section of Molecular Hematology & Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Section of Molecular Hematology and Therapy, Leukemia Department, UT MD Anderson Cancer Center, Houston, TX
3Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
5Memorial Sloan Kettering Cancer Center, New York, NY
6Research Institute of Molecular Pathology (IMP), Vienna, Austria
7NOXXON Pharma AG, Berlin, Germany
8Section of Molecular Hematology & Therapy, Department of Leukemia; Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Tadakazu Akiyama, PhD1*, Shin-ichiro Takayanagi, PhD2*, Yoshimi Maekawa1*, Kohta Miyawaki, MD3*, Fumiaki Jinnouchi, MD3*, Takashi Jiromaru, MD3*, Takeshi Sugio, MD3*, Shinya Daitoku, MD3*, Hirotake Kusumoto, MD3*, Munetake Shimabe, PhD2*, Satoshi Nishikawa2*, Kengo Yamawaki2*, Kousuke Iijima1*, Masanori Hiura1*, Takeshi Takahashi, PhD1*, Yoshikane Kikushige, MD, PhD3*, Hiromi Iwasaki, MD, PhD4, Koichi Akashi, MD, PhD5 and Tomonori Tawara, PhD1*

1R&D Division, Kyowa Hakko Kirin Co., Ltd., Shizuoka, Japan
2R&D Division, Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan
3Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
4Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan
5Kyushu University Hospital, Fukuoka, Japan

Steffan T. Nawrocki, Ph.D.1, Yingchun Han, MD2*, Ronan LE Moigne, PhD3*, Valeria Visconte, PhD2*, Bartlomiej Przychodzen, MSc2*, Mark Rolfe, PhD3, Stevan Djakovic, PhD4*, Daniel Anderson3*, David Wustrow, PhD3*, Han-Jie Zhou3*, Steve Wong, PhD3*, Anjali Advani, MD5, Hetty E. Carraway, MD, MBA6, Jaroslaw P. Maciejewski, MD, Ph.D.2, Mikkael A. Sekeres, MD, MS6, Kevin R. Kelly, MD, PhD7 and Jennifer S. Carew, Ph.D.2

1CTRC Institute for Drug Development, University of Texas Health Science Center at San Antonio, San Antonio, TX
2Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Cleave Biosciences, Burlingame, CA
4Cleave Biosciences, Burlingame
5Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
6Leukemia Program, Cleveland Clinic, Cleveland, OH
7University of Southern California Keck School of Medicine, Los Angeles, CA

Raśl Montiel-Esparza, MD1*, Hanna A. Knaus, MD2*, Joshua F. Zeidner, MD3, Ante Vulic, MD2*, Gabrielle T. Prince, MD2, B. Douglas Smith, MD2, Mark J. Levis, MD, PhD2, Howard Streicher, MD4*, Judith E. Karp, MD2, Leo Luznik, MD2* and Ivana Gojo, MD2

1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
3Department of Medicine, Division of Hematology/Oncology, University of North Carolina-Lineberger Comprehensive Cancer Center, Chapel Hill, NC
4NCI NIH-CTEP, Rockville, MD

Diana Azzam, PhD1*, Claude-Henry Volmar, PhD1*, Al-Ali Hassan, PhD2*, Aymee Perez, PhD3*, Justin M. Watts, MD3*, Fernando Vargas, MD3*, Roy Elias3*, Francisco Vega, MD, PhD4, Arthur Zelent, PhD3, Christopher R. Cogle, MD5, Claes Wahlestedt, PhD1* and Ronan T. Swords, MD, PhD, FRCPI, FRCPath6

1Center for Therapeutic Innovation and Department of Psychiatry and Behavioral Sciences, University of Miami, Miami
2Miami Project to Cure Paralysis, University of Miami, Miami
3Sylvester Comprehensive Cancer Center, University of Miami, Miami
4Department of Pathology and Laboratory Medicine, Division of Hematopathology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, and Jackson Memorial Hospital, Miami, FL
5Division of Hematology/Oncology, University of Florida, Gainesville, FL
6Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Hospitals, Miami, FL

Toshiyuki Nakatani, PhD1*, Ken Uda1*, Takeshi Yamaura1*, Masaru Takasaki1*, Akimi Akashi2*, Fangli Chen, MD2*, Yuichi Ishikawa, MD, PhD2, Fumihiko Hayakawa, MD, PhD2*, Shinji Hagiwara, PhD1*, Hitoshi Kiyoi, MD, PhD2 and Tomoki Naoe, MD, Ph.D.3

1Pharmaceutical and Healthcare Research Laboratories, FUJIFILM Corporation, Kaisei, Japan
2Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
3National Hospital Organization Nagoya Medical Center, Nagoya, Japan

Yixuan Ren, B.S.*, Victoria Brown, M.S.*, Shanhu Hu, Ph.D.*, Jeremy Lopez, B.S.*, Sofija Miljovska, Ph.D.*, Darby Schmidt, Ph.D.*, Michael Bradley, Ph.D.*, Kevin Sprott, Ph.D.*, Eric Olson, Ph.D.*, Christian C. Fritz, PhD* and Yoon Jong Choi, Ph.D.*

Syros Pharmaceuticals, Watertown, MA

Jong Bok Lee1,2*, Weihsu Claire Chen, PhD3*, Elena Streck1,4*, Sohyeong Kang2*, Mark D. Minden, MD, PhD3, John E. Dick, PhD3,5,6 and Li Zhang, PhD MD1,2,6*

1Toronto General Research Institute, University Health Network, Toronto, ON, Canada
2Department of Immunology, University of Toronto, Toronto, ON, Canada
3Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
4Department of Internal Medicine 5, Hematology and Oncology, University of Erlangen-Nuremberg, Erlangen, Germany
5Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada
6Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

Giulia Daniele1*, Clelia Tiziana Storlazzi1*, Cristina Papayannidis, MD, PhD2, Ilaria Iacobucci, PhD3*, Angelo Lonoce1*, Margherita Perricone4*, Mariana Lomiento5*, Fabiana Mammoli5*, Elena Marasco6*, Vilma Mantovani6*, Hilmar Quentmeier, PhD7*, Giorgia Simonetti, PhD8*, Antonella Padella8*, Vincenzo Franza9*, Hans G. Drexler, MD, PhD7, Jie Ding, PhD7*, Orazio Palumbo10*, Massimo Carella10*, Niroshan Nadarajah, M.Sc.11*, Renč Massimiliano Marsano1*, Antonio Palazzo1*, Emanuela Ottaviani8*, Carmen Baldazzi, PhD8*, Nicoletta Testoni8*, Sergio Ferrari, MD, PhD5* and Giovanni Martinelli, MD, PhD2

1Department of Biology, University of Bari, Bari, Italy
2Bologna University School of Medicine, Bologna, Italy
3"Serągnoli" Institute of Hematology, University of Bologna, Bologna, Italy
4Institute of Hematology, Bologna, Italy
5Department of Life Science, University of Modena and Reggio Emilia, Modena, Italy
6Center for Applied Biomedical Research (CRBA), Bologna, Italy
7DSMZ, Braunschweig, Germany
8University of Bologna, Bologna, Italy
9Institute of Hematology "Seragnoli", University of Bologna, Bologna, Italy
10Medical Genetics Unit, IRCCS, San Giovanni Rotondo, Italy
11MLL Munich Leukemia Laboratory, Munich, Germany

Harry Dolstra, PhD1*, Mieke W.H. Roeven, MD2*, Jan Spanholtz, PhD3*, Basav Hangalapura, PhD1*, Marleen Tordoir3*, Frans Maas1*, Marij Leenders1*, Fenna Bohme3*, Nina Kok3*, Carel Trilsbeek1*, Jos Paardekooper1*, Anniek B. Van der Waart, PhD1*, Peter Westerweel, MD, PhD4*, Tjeerd J.F. Snijders, MD5, Gerard M.J. Bos, MD, PhD6, Jan J. Cornelissen, MD, PhD7, Hans Pruijt, MD, PhD8, Gerwin Huls, MD, PhD2*, Aniek de Graaf, PhD1*, Bert A. van der Reijden, PhD1, Nicole M.A. Blijlevens, MD, PhD2, Joop H. Jansen, PhD1, Arnold van der Meer, PhD1*, Jeannette Cany, PhD1*, Frank Preijers, PhD1* and Nicolaas P.M. Schaap, MD, PhD2

1Department of Laboratory Medicine, Radboud university medical center, Nijmegen, Netherlands
2Department of Hematology, Radboud university medical center, Nijmegen, Netherlands
3Glycostem Therapeutics, Oss, Netherlands
4Albert Schweitzer Hospital, Dordrecht, Netherlands
5MST, Enschede, Netherlands
6Dept. of Internal Medicine, University Hospital Maastricht, Maastricht, Netherlands
7Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
8Jeroen Bosch Hospital, S-Hertogenbosch, Netherlands

Stephen E. Kurtz, PhD1*, Daniel Bottomly, MS2*, Beth Wilmot, PhD2*, Shannon K. McWeeney, PhD2*, William Rice, PhD3*, Stephen B Howell, MD4*, Avanish Vellanki3*, Brian J. Druker, MD5 and Jeffrey W. Tyner, PhD6

1Division of Hematology and Medical Oncology, Oregon Health & Science University, Knight Cancer Institute, Portland, OR
2Department of Bioinformatics and Computational Biology, Oregon Health & Science University, Portland, OR
3Aptose Biosciences, Inc., Mississauga, ON, Canada
4Aptose Biosciences Inc., San Diego, CA
5Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR
6Knight Cancer Institute, Oregon Health & Science University, Portland, OR

Silvia Arcangeli1*, Marco Bardelli2*, Sarah Tettamanti1*, Maria Caterina Rotiroti1*, Luca Simonelli2*, Chiara F Magnani1*, Luca Varani2*, Andrea Biondi, Prof, MD1 and Ettore Biagi, MD1*

1Centro Ricerca Tettamanti, Clinica Pediatrica, Universitą Milano Bicocca, Osp. San Gerardo/Fondazione MBBM, Monza (MB), Italy
2Istituto di Ricerca in Biomedicina, Universitą degli Studi della Svizzera Italiana, Bellinzona, Switzerland

Masumi Ueda, MD1, Paolo F. Caimi, MD1, Tammy Stefan2*, Hillard M. Lazarus, MD1, Brenda Cooper, MD1, Marcos de Lima, MD1*, Stanton L. Gerson, MD1 and David N. Wald, MD PhD3*

1Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH
2Department of Pathology, Case Western Reserve University, Cleveland, OH
3Department of Pathology, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

Ivana Gojo, MD1, Jan H. Beumer, PharmD, PhD2,3*, Keith Pratz, MD1, Jiuping Ji4*, Lihua Wang, PhD5*, Michelle A. Rudek, PharmD, PhD1*, Michael A. McDevitt, MD, PhD1, Maria R. Baer, MD6, Amanda Blackford, ScM1*, B. Douglas Smith, MD1, Steven D. Gore, MD7, Hetty E. Carraway, MD, MBA8, Margaret M. Showel, MD1*, Mark J. Levis, MD, PhD1, Amy E. DeZern, MD, MHS1, Douglas Gladstone, MD1, Tania Jain, MD1, Jackie Greer, RN1*, Marie Pouquet, PharmD2*, Ali-walbi Ismail, PharmD, MS2*, James Herman, MD1*, Weijie Poh, PhD1, Larry Karnitz, PhD9*, Scott H. Kaufmann, MD, PhD9, Alice Chen, MD10* and Judith E Karp, MD1

1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
2Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA
3Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA
4National Cancer Institute, National Clinic Target Validation Laboratory, Bethesda, MD
5National Cancer Institute, Frederick, MD
6Greenebaum Cancer Center, University of Maryland Baltimore, Baltimore, MD
7Yale Cancer Center, New Haven, CT
8Leukemia Program, Cleveland Clinic, Cleveland, OH
9Mayo Clinic, Rochester, MN
10Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD

Yanyan Zhang, PhD1*, Erika Saavedra, MD2*, Ruoping Tang3*, Shu-Hui Liu4*, Tod Smeal5*, Valeria Fantin, PhD5*, Stephane De Botton, MD, PhD6*, Ollivier Legrand, MD, PhD7, William Vainchenker, MD, PhD8,9,10, Flavia Pernasetti5* and Fawzia Louache, PhD1,11*

1Gustave Roussy, Inserm U1009, Villejuif, France
2Gustave Roussy, Inserm 1170, Villejuif, France
3Service d'Hematologie et de Therapie cellulaire, Hopital St Antoine, Paris, France
4Oncology-Rinat R&D, Pfizer Worldwide Research and Development, La Jolla, CA
5Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, CA
6Gustave Roussy, Service d'hématologie, Villejuif, France
7Hopital Saint Antoine, APHP, Hematology Dpt, Paris, France
8LABEX GR-Ex, Paris, France
9Université Paris 11, Orsay, France
10INSERM U1170, Institut Gustave Roussy, Villejuif, France
11Université Paris 11, Villejuif, France

Ronan T. Swords, MD, PhD, FRCPI, FRCPath1, Tino Schenk, PhD2*, Sven Stengel, PhD2*, Veronica Sylvina Gil, PhD2*, Kevin R. Petrie, PhD2, Aymee Perez, PhD3*, Rodriguez Ana3*, Justin M. Watts, MD3*, Fernando Vargas, MD3*, Roy Elias3* and Arthur Zelent, PhD3

1Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Hospitals, Miami, FL
2Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom
3Sylvester Comprehensive Cancer Center, University of Miami, Miami

Zezhou Wang, PhD1,2*, Peter Dove2*, Aisha Shamas-Din, PhD1*, Rose Hurren1*, Xiaoming Wang1*, Neil MacLean1*, Marcela Gronda1*, Feng Bo1*, Janessa Li1*, Clarissa Skorupski1*, Wissam Hadri2*, David O'Neill, PhD2,3*, Ahmed Aman, PhD4*, Rima Al-awar, PhD4*, Mark D. Minden, MD, PhD5, Malik Slassi, PhD2* and Aaron D. Schimmer, MD, PhD5

1Princess Margaret Cancer Centre, Toronto, ON, Canada
2Fluorinov Pharma Inc., Toronto, ON, Canada
3Fight Against Cancer Innovation Trust, Toronto, ON, Canada
4Ontario Institute for Cancer Research, Toronto, ON, Canada
5Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Ka Leung Li, BSc (Hons)1,2*, Sarah C Bray, PhD1,2*, Diana Iarossi, BSc (Hons)1,2*, Julian Adams, PhD1,2*, Longjin Zhong1,2*, Ben Noll, BSc (Hons)1,2*, Muhammed H Rahaman, BSc (Hons)1,2*, Jennifer Richmond, BSc(Hons)3*, Luen Bik To, MBBS, PhD4,5, Ian D Lewis, MBBS, PhD, FRACP, FRCPA1,4,6, Richard B Lock, PhD3, Shudong Wang, PhD1,2* and Richard J D'Andrea, PhD1,2

1Centre for Cancer Biology, SA Pathology & University of South Australia, Adelaide, Australia
2School of Pharmacy and Medical Sciences, Division of Health Sciences, University of South Australia, Adelaide, Australia
3Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia
4School of Medicine, University of Adelaide, Adelaide, Australia
5Department of Haematology, SA Pathology and Royal Adelaide Hospital, Adelaide, Australia
6Haematology, SA Pathology, Adelaide, Australia

Watkins M Krystal, MS*, Russell Walker, MS*, Nathan Fishkin, PhD*, Charlene Audette*, Yelena Kovtun, PhD* and Angela Romanelli, PhD

ImmunoGen, Inc., Waltham, MA

David S Millan, PhD*, Monica A Alvarez Morales, MS*, Kenneth J Barr, PhD*, Daniel Cardillo, MS*, Alan Collis, PhD*, Christopher J Dinsmore, PhD*, Jaime A Escobedo, PhD*, Kevin P Foley, PhD*, Torsten Herbertz, PhD*, Stephen Hubbs, BS*, Goss S Kauffman, BS*, Katherine J Kayser-Bricker, PhD*, Mark T Kershaw, MSc*, George P Luke, PhD*, Matthew W Martin, PhD*, Crystal McKinnon, BS*, Rachel L Mendes, MS*, Kristina R Muskiewicz, MA*, Shawn ER Schiller, MS*, Patricia Soulard, MS*, Adam C Talbot, PhD*, Duncan Walker, PhD, Lili Yao, MS* and Grace L Williams, PhD*

FORMA Therapeutics, Watertown, MA

*signifies non-member of ASH